TNFα induces rapid activation and nuclear translocation of telomerase in human lymphocytes

Biochemical and Biophysical Research Communications

Volumn 316, Issue 2, 2004, Pages 528-532

  Akiyama, Masaharu ^a   Yamada, Osamu ^b   Hideshima, Teru ^c   Yanagisawa, Takaaki ^a   Yokoi, Kentaro ^a   Fujisawa, Kohji ^a   Eto, Yoshikatsu ^a   Yamada, Hisashi ^a   Anderson, Kenneth C ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Akt; hTERT; NF B; Nuclear translocation; Telomerase; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SN 50; TELOMERASE; UNCLASSIFIED DRUG; WORTMANNIN; AKT1 PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOPLASM; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOCYTE; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN TRANSPORT; ACTIVE TRANSPORT; CELL CULTURE; CELL NUCLEUS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; LYMPHOCYTES; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TELOMERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542512436     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.02.080     Document Type: Article

References (14)

1. Blackburn E.H. Switching and signaling at the telomere. Cell. 106:2001;661-673.
2. Akiyama M., Hideshima T., Munshi N.C., Anderson K.C. Telomerase inhibitors as anticancer therapy. Curr. Med. Chem.-Anti-Cancer Agents. 2:2002;567-575.
3. Yamada O., Motoji T., Mizoguchi H. Upregulation of telomerase activity in human lymphocytes. Biochim. Biophys. Acta. 1314:1996;260-266.
4. Kurosaka D., Yasuda J., Yoshida K., Yokoyama T., Ozawa Y., Obayashi Y., Kingetsu I., Saito S., Yamada A. Telomerase activity and telomere length of peripheral blood mononuclear cells in SLE patients. Lupus. 12:2003;591-599.
5. Kyo S., Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene. 21:2002;688-697.
6. Kang S.S., Kwon T., Kwon D.Y., Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274:1999;13085-13090.
7. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., Chauhan D., Richardson P., Munshi N.C., Anderson K.C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62:2002;3876-3882.
8. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., Chauhan D., Richardson P., Munshi N.C., Anderson K.C. Nuclear factor-κB p65 mediates tumor necrosis factor α-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 63:2003;18-21.
9. Liu K., Hodes R.J., Weng N. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol. 166:2001;4826-4830.
10. Klapper W., Qian W., Schulte C., Parwaresch R. DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia. 17:2003;2007-2015.
11. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N., Treon S.P., Anderson K.C. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic application. Blood. 99:2002;4079-4086.
12. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 16:2002;1053-1068.
13. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 17:2003;590-603.
14. Ramirez R., Carracedo J., Jimenez R., Canela A., Herrera E., Aljama P., Blasco M.A. Massive telomere loss is an early event of DNA damage-induced apoptosis. J. Biol. Chem. 278:2003;836-842.